Replies to post #215121 on Biotech Values

[RockRat]

ACHN also reported some early data for C3G. n=2 and open label, but signal was good enough to demonstrate proof of concept and move along. I have a position, and think this may be a good time to add on the weakness. With the Hep C program dead and the J&J overhang gone, this is an interesting play on their complement factor D inhibition program.

Regards, RockRat

[dangerM]

> ACHN -17.9%/AH—JNJ to sell entire stake (18.4M shares)

Yes, but not before Christmas! That's when the lock-up period ends.

Cf. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134535662
"the date that is sixty days after the first public announcement of top-line clinical results from Janssen’s phase IIb OMEGA-1 clinical trial"

The the first public announcement is about Oct 23rd, cf. http://ir.achillion.com/releasedetail.cfm?releaseid=1044856